Doubling Down On Antibiotic Incentives: Congress, Obama Administration Drafting Proposals
This article was originally published in RPM Report
Executive Summary
The 2012 FDA Safety & Innovation Act included important new incentives for antibiotic developers. But the Obama Administration and key legislators want to do even more to revive R&D in the space. What will it take to bring Big Pharma back?
You may also be interested in...
A Tamer 'Wildcard'? Antibiotic Exclusivity Would Have More Strings Attached In New Bill
Advocates for antibiotic incentives are hoping to attach 'wildcard' patent proposal to pending PAHPA reauthorization bill; New conditions on exclusivity are intended to make approach more politically viable – and assure favorable CBO score.
Antibiotic Incentives: Prize Fund Is Focus Of Presidential Report On Incentives
Upcoming White House report on antibiotic incentives will provide a strong endorsement of one-time payments to reward successful development of new therapeutics. That is a mixed blessing for advocates for legislative action for incentives who are focusing on 'wildcard' patents.
‘Wildcard’ Patents: Why A REVAMP-ed Proposal Might Work In 2017
Before election day, the idea of a new transferrable exclusivity incentive seemed like an extreme long shot for enactment. But now advocates think it has a real chance – and a strategy to redraft the idea to answer Democratic critics and avoid a high CBO score.